A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

Must have received: erythropoiesis-stimulating agent (erythropoiesis-stimulating agent, luspatercept) — for LR-MDS-related anemia

Received prior treatment with Erythropoiesis-stimulating agent (ESA) OR luspatercept for LR-MDS-related anemia that is relapsed/refractory to therapy. Participants intolerant to prior ESA or luspatercept will fulfill this inclusion criterion provided the definition below is met.

Cannot have received: JAK1/2 inhibitor

Prior treatment with Janus kinase (JAK)1/2 inhibitors

Cannot have received: ACTRIIb IMiDs

Exception: if ≤1 week of treatment received; provided last dose was ≥8 weeks from randomization

ACTRIIb IMiDs (if ≤1 week of treatment received; provided last dose was ≥8 weeks from randomization)

Cannot have received: ACTRIIb receptor ligand trap other than luspatercept

ACTRIIb receptor ligand trap other than luspatercept

Cannot have received: hypomethylating agent

Hypomethylating agents or other disease modifying agents (i.e., IMiDs) and immunosuppressive therapy for MDS

Cannot have received: immunomodulatory drug

Hypomethylating agents or other disease modifying agents (i.e., IMiDs) and immunosuppressive therapy for MDS

Cannot have received: immunosuppressive therapy

Hypomethylating agents or other disease modifying agents (i.e., IMiDs) and immunosuppressive therapy for MDS

Cannot have received: erythropoiesis-stimulating agent

Exception: within 4 weeks, or 8 weeks for long-acting ESA

ESA within 4 weeks, or 8 weeks for long-acting ESA

Cannot have received: growth factor (G-CSF, GM-CSF)

Exception: within 4 weeks

Growth factors (i.e., G-CSF, GM-CSF) within 4 weeks

Cannot have received: (luspatercept)

Exception: within 8 weeks

Luspatercept within 8 weeks

Cannot have received: investigational agent

Exception: within 4 weeks or 5 half-lives, whichever is longer

Investigational agents within 4 weeks or 5 half-lives, whichever is longer

Cannot have received: corticosteroid

Exception: for treatment of the underlying disease within 28 days. Supportive care use of steroids for non-MDS indications may be used provided participant is on a stable dose equivalent to ≤10 mg prednisone per day.

Corticosteroids for treatment of the underlying disease within 28 days. Supportive care use of steroids for non-MDS indications may be used provided participant is on a stable dose equivalent to ≤10 mg prednisone per day.

Cannot have received: anti-MDS therapy

Exception: not otherwise listed within 28 days or 5 half-lives whichever is longer

Other active anti-MDS therapy not otherwise listed within 28 days or 5 half-lives whichever is longer

Cannot have received: stem cell transplant (allogeneic stem cell transplant, autologous stem cell transplant)

Prior allogeneic or autologous stem cell transplant